Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05818358
Other study ID # HS25221
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 1, 2023
Est. completion date December 31, 2024

Study information

Verified date March 2024
Source University of Manitoba
Contact Peter C Zahradka, PhD
Phone 2042353507
Email peter.zahradka@umanitoba.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single site, single-blinded, controlled randomized crossover clinical trial designed to compare the effects of black beans or whole grains or white rice at breakfast on postprandial vascular responses in males and females with arterial stiffness (n=10). Eligible participants will be asked to attend 3 in-person visits for comparative testing of black beans versus whole grains versus white rice.


Description:

This is a single site, single-blinded, randomized, controlled crossover study designed to compare the vascular responses of males and females with arterial stiffness before and 2 hours after ingestion of black beans or whole grains (wheat) or white rice (isocaloric comparator). Recruitment will consist of a total of 10 participants with arterial stiffness. Participants will be recruited through advertisement from the local community. The study will be conducted at the Asper Clinical Research Institute, St. Boniface Hospital. Participants will be asked to provide written informed consent prior to participation in the study. Participants who have provided written consent will be asked to attend an in-patient screening visit to provide a fasting blood sample (and females a urine sample) and assess the presence of arterial stiffness (by PWV) to determine eligibility. Should the participant be eligible to participate, they will be scheduled for three study visits to obtain fasting blood samples and assess postprandial blood vessel function. During the first study visit period, participants will be asked to complete a Food Habits Questionnaire.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date December 31, 2024
Est. primary completion date April 30, 2024
Accepts healthy volunteers No
Gender All
Age group 45 Years to 65 Years
Eligibility Inclusion Criteria: 1. Male, or non-pregnant, non-lactating female, 45 to 65 years of age; 2. Brachial-ankle pulse wave velocity >1400 cm/s on at least one side; 3. Plasma creatinine =265 µmol/L; 4. Aspartate aminotransferase <160 U/L, andalanine aminotransferase <150 U/L; 5. Glycated hemoglobin =6.5%; 6. LDL-cholesterol <5 mmol/L; 7. Stable regime if taking vitamin and mineral/dietary/herbal supplements for the past 1 month and while participating in the study; 8. Has not donated blood or blood products (e.g. platelets) during the past 2 months and willing to continue doing so while participating in the study; 9. Not participating in another dietary intervention trial for the past month and willing to not start another dietary intervention trial for the duration of this study; 10. Willing to comply with the protocol requirements and procedures; 11. Willing to provide informed consent. Exclusion Criteria: 1. Has experienced a cardiovascular event (e.g. heart attack, stroke) or had a surgical procedure for cardiovascular disease (e.g. bypass, stent), presence of clinically diagnosed cardiac arrhythmia or valve stenosis, chronic renal disease, liver disease (with exception of fatty liver), lung disease, rheumatoid arthritis, immune disorder or disease (e.g. multiple sclerosis, leukemia), cancer in the previous 5 years, neurological disorders, or gastrointestinal disorders; 2. Taking vasoactive medications (e.g., ACE inhibitors, ARBs, AGE-breakers, thiazolidinediones, beta-blockers, statins, insulin, etc.); 3. Blood pressure >160 mmHg systolic and/or >100 mmHg diastolic; 4. History of gastrointestinal reactions or allergies to beans, bean flour, wheat, wheat flour, gluten, or rice; 5. Body weight exceeds the capacity of the DEXA (350 lbs); 6. Current (within the past 30 days) bacterial, viral or fungal infection; 7. Bleeding disorder; 8. Amputations of upper or lower extremities on both sides; 9. Any acute medical condition or surgical intervention within the past 3 months; 10. Drug and/or alcohol abuse; 11. Psychological disorder(s); 12. Unable to fast overnight; 13. Unable to take prescribed medication without food; 14. Unable to obtain vascular function measurements and/or blood sample at the screening or first study visits; 15. Not fully vaccinated for COVID-19.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
black beans
¾ cup of cooked black beans
wheat berries
¾ cup of cooked whole wheat grain
white rice
¾ cup of cooked white rice

Locations

Country Name City State
Canada Asper Clinical Research Institute Winnipeg Manitoba

Sponsors (1)

Lead Sponsor Collaborator
University of Manitoba

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline Augmentation index at 2 hours Pulse wave analysis using a Mobil-O-Graph PWA Monitor will be used to measure the augmentation index (AIx), an indicator of arterial stiffness, prior to consumption of the test products, and at 2 hours post-consumption. Time points 0 (prior to consumption) and 2 hours post consumption.
Primary Change from baseline Pulse wave velocity at 2 hours Pulse wave analysis using a Mobil-O-Graph PWA Monitor will be used to measure the pulse wave velocity (PWV), an indicator of arterial stiffness, prior to consumption of the test products, and at 2 hours post-consumption. Time points 0 (prior to consumption) and 2 hours post consumption.
Primary Change from baseline Reflection magnitude at 2 hours Pulse wave analysis using a Mobil-O-Graph PWA Monitor will be used to measure the reflection magnitude, an indicator of arterial stiffness, prior to consumption of the test products, and at 2 hours post-consumption. Time points 0 (prior to consumption) and 2 hours post consumption.
Secondary C-reactive protein A fasting venous blood sample will be analyzed for C-reactive protein to assess inflammatory status Time points 0 (prior to consumption) and 2 hours post consumption.
Secondary soluble VCAM1 A fasting venous blood sample will be analyzed for soluble VCAM1 (vascular cell adhesion molecule-1) to assess changes in endothelial function Time points 0 (prior to consumption) and 2 hours post consumption.
See also
  Status Clinical Trial Phase
Recruiting NCT06133634 - Fisetin to Improve Vascular Function in Older Adults Phase 1/Phase 2
Completed NCT05872139 - Role of Mitochondrial-derived Oxidative Stress to Promote Vascular Endothelial Dysfunction in Non-exercisers With Aging N/A
Recruiting NCT04558450 - Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN) N/A
Recruiting NCT05095688 - Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
Not yet recruiting NCT05943457 - Vitamin K2 Supplementation in Adult Episodic Migraine N/A
Not yet recruiting NCT04900610 - The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis N/A
Completed NCT02226055 - An Investigation Into the Cardiovascular Risk and Aetiology of CKDu in Sri Lanka N/A
Completed NCT01559896 - Egg Protein Hydrolysate and Vascular Function N/A
Completed NCT04049162 - Blueberry Enhances Activity and Cognition Through Increased Vascular Efficiency N/A
Not yet recruiting NCT06440369 - Physical Activity and Cardiovascular Risk N/A
Completed NCT05537246 - The Relationship Between Arterial Stiffness and Hemodynamic Responses in Patients With Spinal Anesthesia
Completed NCT06151054 - Relationship Between Aortic Parietal Inflammation on 18F-FDG PET Scan and Arterial Stiffness as a Function of Age
Completed NCT02218268 - Arterial Stiffness in Type I Diabetes Mellitus N/A
Completed NCT00547040 - Arterial Stiffness and Calcifications in Incident Renal Transplant Recipients
Completed NCT02821780 - CADASIL Disease Discovery
Completed NCT05719090 - Acute Effects of Autoregulated and Non-autoregulated Blood Flow Restrictive Exercise on Indices of Arterial Stiffness N/A
Completed NCT04549324 - Sleep Apnea, Coronary Atherosclerosis and Heart Failure in Diabetes Patients With Nephropathy
Completed NCT05022498 - Individual Variability of Coronary Heart Disease Risk Markers and Sleep Responses to Exercise N/A
Completed NCT03415880 - Light Intensity Physical Activity Trial N/A
Completed NCT03560804 - Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect of Two Drugs N/A